JNJ Blowout Earnings Mask Persistent Risks

What happened

J&J reported a blowout quarter, raising full-year revenue and EPS guidance and putting it on track to exceed $100B in annual revenue for the first time. However, the headline strength masks a still-fragile operating picture: STELARA sales collapsed 59.7% YoY, CVS Caremark's formulary switch away from Stelara effective July 1, 2026 threatens a second leg of erosion, and talc litigation remains an unquantified overhang with 75,000+ plaintiffs. Management's raised guidance likely reflects lower incremental spending and a stronger-than-expected oncology launch pipeline, but the core thesis risks—accelerating biosimilar erosion and unbounded legal liability—are unchanged. The market's enthusiasm may be premature given that the next two quarters will reveal whether the growth drivers can truly offset the impending payer-driven step-down.

Implication

The earnings beat is a tactical positive but does not resolve the two dominant asymmetric risks: STELARA erosion post-CVS switch and talc liability. Investors should remain on the sidelines until Q3 results confirm that newer drugs (TREMFYA, DARZALEX) are backfilling the decline and no material talc accrual emerges. The current valuation (P/E ~26.5) embeds optimism that the biosimilar transition will be orderly—a bet that may not pay off if payer actions accelerate. Patience is warranted; a better entry point is likely after the July 1 CVS formulary change and its impact are disclosed.

Thesis delta

The strong report and guidance raise near-term sentiment but do not alter the WAIT rating. The thesis still requires proof of immunology stabilization and bounded talc exposure in Q2–Q3 FY2026. The CVS formulary switch remains the most immediate downside catalyst, and without clarity on that impact, fundamental risk asymmetry still favors waiting.